# N-Acetyl Cystein and Contrast Nephropathy

> **NCT01820195** · PHASE3 · UNKNOWN · sponsor: **Imam Khomeini Hospital** · enrollment: 549 (estimated)

## Conditions studied

- Chronic Kidney Disease Stage 2
- Radiographic Contrast Agent Nephropathy

## Interventions

- **DRUG:** Oral N-Acetyl Cystein
- **DRUG:** IV N-Acetyl Cystein
- **DRUG:** Placebo group

## Key facts

- **NCT ID:** NCT01820195
- **Lead sponsor:** Imam Khomeini Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 549 (ESTIMATED)
- **Last updated:** 2013-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820195, "N-Acetyl Cystein and Contrast Nephropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01820195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*